Mirtazapin Hexal (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Hexal, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for systemic use. It is prescribed for the treatment of major depressive disorder in adult patients, helping to improve mood, sleep and appetite where other agents have been insufficient.

GNH USA supplies Mirtazapin Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is indicated for depressive disorders and works by modulating noradrenergic and serotonergic pathways.

- Major depressive disorder: alleviates depressive symptoms and improves overall mood in adult patients.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Fatigue

Serious or Rare Side Effects: - Severe neutropenia or agranulocytosis - Serotonin syndrome, especially when combined with other serotonergic agents - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Emergence or worsening of suicidal thoughts, particularly early in treatment

Before initiating therapy, consider the following precautions: - Assess psychiatric history: evaluate for suicidal thoughts and mood instability. - Monitor weight: patients may experience increased appetite and weight gain. - Check liver function: use caution in hepatic impairment. - Avoid abrupt discontinuation: taper under medical supervision to prevent withdrawal symptoms. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome. - Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic agents: increased risk of serotonin syndrome. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels. - Alcohol: additive central nervous system depression and sedation.

Moderate Interactions (Monitor Closely): - CNS depressants (benzodiazepines, opioids): enhanced sedative effect. - Anticholinergic drugs: may worsen dry mouth and constipation. - Warfarin: possible alteration of INR; monitor coagulation parameters.